UNCY

SEC source: 0001213900-26-058662 · ownership.xml · derivative · entry 2

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,300

Underlying: Common Stock · 42,100 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-058662 · ownership.xml · derivative · entry 1

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,200

Underlying: Common Stock · 84,200 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-059559 · ownership.xml · derivative · entry 1

Townsend John · CIK 0001511906 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,500

Underlying: Common Stock · 169,500 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-059560 · ownership.xml · derivative · entry 1

Jermasek Douglas · CIK 0001955273 · EVP, Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,500

Underlying: Common Stock · 169,500 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-059558 · ownership.xml · derivative · entry 1

Gupta Pramod · CIK 0001857927 · EVP, Pharmaceuticals and BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,500

Underlying: Common Stock · 169,500 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-060079 · ownership.xml · derivative · entry 2

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,300

Underlying: Common Stock · 42,100 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-060079 · ownership.xml · derivative · entry 1

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,200

Underlying: Common Stock · 84,200 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-060080 · ownership.xml · derivative · entry 1

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762,200

Underlying: Common Stock · 762,200 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068921 · ownership.xml · derivative · entry 2

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,300

Underlying: Common Stock · 42,100 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068921 · ownership.xml · derivative · entry 1

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,200

Underlying: Common Stock · 84,200 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068922 · ownership.xml · derivative · entry 1

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762,200

Underlying: Common Stock · 762,200 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068917 · ownership.xml · derivative · entry 1

Townsend John · CIK 0001511906 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,500

Underlying: Common Stock · 169,500 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068920 · ownership.xml · derivative · entry 2

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,300

Underlying: Common Stock · 42,100 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068920 · ownership.xml · derivative · entry 1

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,200

Underlying: Common Stock · 84,200 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068919 · ownership.xml · derivative · entry 1

Gupta Pramod · CIK 0001857927 · EVP, Pharmaceuticals and BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,500

Underlying: Common Stock · 169,500 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-068915 · ownership.xml · derivative · entry 1

Jermasek Douglas · CIK 0001955273 · EVP, Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,500

Underlying: Common Stock · 169,500 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-082273 · ownership.xml · derivative · entry 1

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,941

Underlying: Common Stock · 47,941 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-26-082270 · ownership.xml · derivative · entry 1

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,941

Underlying: Common Stock · 47,941 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

F1 · derivative.expiration_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001213900-25-080808 · ownership.xml · derivative · entry 2

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P.

Disclosed balance after: 0

Underlying: Common Stock · 652,900 shares

Expires not disclosed

F3 · derivative.exercise_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

F3 · derivative.expiration_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-25-080808 · ownership.xml · nonDerivative · entry 1

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P.

Disclosed balance after: 1,789,915

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-25-069304 · ownership.xml · derivative · entry 1

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,200

Underlying: Common Stock · 21,200 shares

Expires 2035-07-28

SEC source: 0001213900-25-069303 · ownership.xml · derivative · entry 1

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 968,951

Underlying: Common Stock · 325,000 shares

Expires 2035-07-28

F1 · derivative.exercise_date: 81,250 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-25-069302 · ownership.xml · derivative · entry 1

Townsend John · CIK 0001511906 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,557

Underlying: Common Stock · 10,000 shares

Expires 2035-07-28

F1 · derivative.exercise_date: 2,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-25-069306 · ownership.xml · derivative · entry 1

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,200

Underlying: Common Stock · 21,200 shares

Expires 2035-07-28

SEC source: 0001213900-25-069305 · ownership.xml · derivative · entry 1

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,286

Underlying: Common Stock · 21,200 shares

Expires 2035-07-28

SEC source: 0001213900-25-069300 · ownership.xml · derivative · entry 1

Jermasek Douglas · CIK 0001955273 · EVP of Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,500

Underlying: Common Stock · 10,000 shares

Expires 2035-07-28

F1 · derivative.exercise_date: 2,500 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-25-069301 · ownership.xml · derivative · entry 1

Gupta Pramod · CIK 0001857927 · EVP, Pharmaceuticals and BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301,986

Underlying: Common Stock · 90,000 shares

Expires 2035-07-28

F1 · derivative.exercise_date: 22,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-25-015152 · ownership.xml · derivative · entry 2

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P.

Disclosed balance after: 3,119.21

Underlying: Common Stock · 1,400,000 shares

Expires not disclosed

F3 · derivative.exercise_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

F3 · derivative.expiration_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-25-015152 · ownership.xml · nonDerivative · entry 1

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P.

Disclosed balance after: 11,370,152

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-24-086928 · ownership.xml · derivative · entry 2

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P.

Disclosed balance after: 3,885.21

Underlying: Common Stock · 5,500,000 shares

Expires not disclosed

F3 · derivative.exercise_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

F3 · derivative.expiration_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.

F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-24-086928 · ownership.xml · nonDerivative · entry 1

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P.

Disclosed balance after: 9,970,152

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001213900-24-069034 · ownership.xml · derivative · entry 1

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,439,505

Underlying: Common Stock · 232,868 shares

Expires 2034-08-12

F1 · derivative.exercise_date: 58,217 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-069038 · ownership.xml · derivative · entry 1

Townsend John · CIK 0001511906 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 915,565

Underlying: Common Stock · 40,256 shares

Expires 2034-08-12

F1 · derivative.exercise_date: 10,064 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-069039 · ownership.xml · derivative · entry 1

Gupta Pramod · CIK 0001857927 · EVP, Pharmaceuticals and BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,119,862

Underlying: Common Stock · 81,750 shares

Expires 2034-08-12

F1 · derivative.exercise_date: 20,438 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-069037 · ownership.xml · derivative · entry 1

Jermasek Douglas · CIK 0001955273 · EVP of Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,055,000

Underlying: Common Stock · 81,750 shares

Expires 2034-08-12

F1 · derivative.exercise_date: 20,438 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-033828 · ownership.xml · derivative · entry 1

Gupta Shalabh K. · CIK 0001864917 · Director · CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,206,637

Underlying: Common Stock · 1,319,583 shares

Expires 2034-04-15

F1 · derivative.exercise_date: 329,896 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-033833 · ownership.xml · derivative · entry 1

Townsend John · CIK 0001511906 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 875,309

Underlying: Common Stock · 228,119 shares

Expires 2034-04-15

F1 · derivative.exercise_date: 57,030 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-033831 · ownership.xml · derivative · entry 1

Jermasek Douglas · CIK 0001955273 · EVP of Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,973,250

Underlying: Common Stock · 463,250 shares

Expires 2034-04-15

F1 · derivative.exercise_date: 115,813 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-24-033829 · ownership.xml · derivative · entry 1

Gupta Pramod · CIK 0001857927 · EVP, Pharmaceuticals and BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,038,112

Underlying: Common Stock · 463,250 shares

Expires 2034-04-15

F1 · derivative.exercise_date: 115,813 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-23-075012 · ownership.xml · derivative · entry 1

Kenkare-Mitra Sara · CIK 0001895592 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2033-09-05

SEC source: 0001213900-23-075008 · ownership.xml · derivative · entry 1

Aggarwal Gaurav · CIK 0001551965 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2033-09-05

SEC source: 0001213900-23-075010 · ownership.xml · derivative · entry 1

Ryan John L · CIK 0001679825 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,775

Underlying: Common Stock · 112,147 shares

Expires 2033-09-05

F1 · derivative.exercise_date: 37,382 options vest on June 26, 2024, 37,382 options vest on June 26, 2025 and 37,383 vest on June 26, 2026.

SEC source: 0001213900-23-075014 · ownership.xml · derivative · entry 1

Laumas Sandeep · CIK 0001721664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,864

Underlying: Common Stock · 189,236 shares

Expires 2033-09-05

F1 · derivative.exercise_date: 63,079 options vest on June 26, 2024, 63,079 options vest on June 26, 2025 and 63,078 vest on June 26, 2026.

SEC source: 0001213900-23-072251 · ownership.xml · derivative · entry 1

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,988,798

Underlying: Common Stock · 4,684,775 shares

Expires 2033-08-28

F1 · derivative.exercise_date: 1,171,194 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-23-072249 · ownership.xml · derivative · entry 1

Townsend John · CIK 0001511906 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 647,190

Underlying: Common Stock · 570,329 shares

Expires 2033-08-28

F1 · derivative.exercise_date: 142,582 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-23-072252 · ownership.xml · derivative · entry 1

Gupta Pramod · CIK 0001857927 · EVP, Pharmaceuticals and BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,574,862

Underlying: Common Stock · 1,355,000 shares

Expires 2033-08-28

F1 · derivative.exercise_date: 338,750 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-23-072246 · ownership.xml · derivative · entry 1

Jermasek Douglas · CIK 0001955273 · EVP of Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,510,000

Underlying: Common Stock · 1,355,000 shares

Expires 2033-08-28

F1 · derivative.exercise_date: 338,750 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter.

SEC source: 0001213900-23-056848 · ownership.xml · derivative · entry 5

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,275

Underlying: Series A-5 Convertible Preferred Stock · 115,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

F5 · derivative.expiration_date: The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.

SEC source: 0001213900-23-056848 · ownership.xml · derivative · entry 4

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,047

Underlying: Series A-4 Convertible Preferred Stock · 72,047 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

F4 · derivative.expiration_date: The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.

SEC source: 0001213900-23-056848 · ownership.xml · derivative · entry 3

Gupta Shalabh K. · CIK 0001864917 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,252

Underlying: Series A-3 Convertible Preferred Stock · 79,252 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.

F3 · derivative.expiration_date: The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.